Spherix’s coverage of emerging rheumatology indications focuses on evolving markets where a paradigm shift is expected in the coming years.
Prepping for the pipeline
Giant Cell Arteritis (US)
Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Methodology: Insights are based on analyses of quantitative data collected from an online survey of specialists, patients, and leading KOLs recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents and select KOLs.
Sample Size and Frequency
Annual report (n=100-200 physicians)
Qualitative interviews (n=6-8 physicians, n=2-3 KOLs)